Effect of Dash Diet and Acupuncture on Hypertention in Postmenopausal Women
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
45 of post menopausal women divided into three groups A,B,C
- Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.
- Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.
- Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Elsharqia
-
Abu hammad, Elsharqia, Egypt, 44661
- Alaa Nabil Elsayed Mohamed
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Their body mass index will be ranged from 25 -29.9 kg/m2
- All patients will be medically stable when attending the study.
- The DASH eating plan of 1800 kcal per day will be used in the study.
Exclusion Criteria:
- Auditory and visual problems.
- Chronic renal failure.
- Myocardial infarction or arrythmias with heart failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: effect of dash diet and acupuncture on hypertention in post menopausal women
|
acupuncture
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
blood pressure
Time Frame: 3 months
|
it will be measured by sphygmomanometer pre and post treatment
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sodium and potassium levels
Time Frame: 3 months
|
it will be measured by blood analysis pre and post treatment
|
3 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
assessment of quality of life
Time Frame: 3 months
|
it will be measured by sf 36 questionnaire pre and post treatment
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- P.T.REC/012/003872
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.